Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PRIVA-IRBESARTAN - Health Canada Drug Approval Details

Approvals/Health Canada/PRIVA-IRBESARTAN

Authorized

STANDARD

PRIVA-IRBESARTAN

pharmapar inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 3184d60abec71b4a
Company: pharmapar inc
Type: Standard

Approval Details

Approval Id: 3184d60abec71b4a
Drug Approval Canada Name: PRIVA-IRBESARTAN
Product Name: PRIVA-IRBESARTAN
Status: Cancelled Post Market
Status Date: 2022-07-29
Original Market Date: 2016-05-13
Din: 02446510
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 24:32.08
Atc Original: C09CA04 IRBESARTAN
Atc Name: c 09 ca 04
Aig Number: 0131700003
Company Name: pharmapar inc
Company Address: 1565 Boul Lionel-Boulet, Varennes, Quebec, Canada, J3X 1P7

Active Ingredients

IRBESARTAN

300 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

3184d60abec71b4a

Type

Standard

Back to Health Canada Approvals